These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26645401)

  • 41. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Xiao AJ; Huntington JA; Long J; Caro L
    Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
    Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
    J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
    Rodriguez BA; Girotto JE; Nicolau DP
    Curr Pediatr Rev; 2018; 14(2):97-109. PubMed ID: 29521242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
    J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!
    Teleb M; Soto-Ruiz E; Dominguez DC; Antony S
    Infect Disord Drug Targets; 2018; 18(1):81-85. PubMed ID: 27411471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
    Aitken SL; Kontoyiannis DP; DePombo AM; Bhatti MM; Tverdek FP; Gettys SC; Nicolau DP; Nunez CA
    Pediatr Infect Dis J; 2016 Sep; 35(9):1040-2. PubMed ID: 27254038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Grohs P; Taieb G; Morand P; Kaibi I; Podglajen I; Lavollay M; Mainardi JL; Compain F
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
    Shortridge D; Castanheira M; Pfaller MA; Flamm RK
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
    Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
    Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam.
    Connor KA
    AACN Adv Crit Care; 2016 Oct; 27(4):353-357. PubMed ID: 27959289
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.
    Chen GJ; Pan SC; Foo J; Morel C; Chen WT; Wang JT
    J Microbiol Immunol Infect; 2019 Oct; 52(5):807-815. PubMed ID: 31029529
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.
    Monogue ML; Stainton SM; Baummer-Carr A; Shepard AK; Nugent JF; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.